ArticleClinical kidney journal2026
Design of the Japan Kidney Association-Pemafibrate Intervention for Chronic Kidney Disease patients Study (JKAPI-CKD Study).
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertriglyceridemia has attracted considerable attention as a residual cardiovascular risk factor in patients with chronic kidney disease (CKD). Pemafibrate, a selective peroxisome proliferator-activated receptor α modulator, is a novel therapeutic option for hypertriglyceridemia in patients with CKD, and is associated with fewer kidney adverse events in this population compared with conventional fibrates. Although appropriate management of hypertriglyceridemia may contribute to improved kidney outcomes, evidence regarding the efficacy and safety of pemafibrate to reduce CKD progression is unknown. The aim of this study is to investigate the effect of pemafibrate on the rate of change in estimated glomerular filtration rate (eGFR) slope in patients with CKD. Methods: The Japan Kidney Association-Pemafibrate Intervention for Chronic Kidney Disease patients (JKAPI-CKD) study is a prospective, multicenter, open-label, parallel-group, randomized controlled trial. The study will enroll 2200 adults with CKD, defined as eGFR ≥20 ml/min/1.73 m Results: On 1 December 2025, a total of 2328 participants had been enrolled, completing the participant enrollment. Conclusions: The JKAPI-CKD study is anticipated to yield novel insights into the renoprotective effects of pemafibrate in patients with CKD and establish new evidence supporting its use for the management of dyslipidemia in this population.Trial registration: Japan Registry of Clinical Trials (jRCTs031240097).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.